For the Inventor, By the Inventor

Enter assignee name

Bengaluru, India

Aurigene Oncology Limited

USPTO Granted Patents = 16

EPO Patents = 5

Forward Citations = 6

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Muralidhara Ramachandra (8 out of 29 patents)

Pottayil Govindan Nair Sasikumar (5 out of 21 patents)

Susanta Samajdar (5 out of 26 patents)

4. Seetharamaiah Setty Sudarshan Naremaddepalli (4 out of 17 patents)

5. Chennakrishnareddy Gundala (2 out of 3 patents)

6. Chetan Pandit (2 out of 10 patents)

7. Pottayil Govindan N Sasikumar (2 out of 7 patents)

8. Venkateshwar Rao Gummadi (2 out of 15 patents)

9. Leena Khare Satyam (2 out of 3 patents)

10. Dinesh Chikkanna (1 out of 5 patents)

11. Girish Chandrappa Daginakatte (1 out of 3 patents)

12. Kiran Aithal Balkudru (1 out of 2 patents)

13. Brian R Hearn (1 out of 11 patents)

14. Ramulu Poddutoori (1 out of 13 patents)

15. Subhendu Mukherjee (1 out of 10 patents)

16 patents: Sort by Forward Citations

1. 12428379 - Acylsulfonamide KAT6A inhibitors (2025-09-30),

2. 12410193 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2025-09-09),

3. 12377088 - Substituted tetrahydroquinolinone compounds as ROR gamma modulators (2025-08-05),

4. 12331023 - Substituted heterocyclyl derivatives as CDK inhibitors (2025-06-17),

5. 12290507 - Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors (2025-05-06),

6. 12268670 - Combination of small molecule CD-47 inhibitors with other anti-cancer agents (2025-04-08),

7. 12226402 - Dual inhibitors of TIM-3 and PD-1 pathways (2025-02-18),

8. 12187689 - Crystalline forms of 3-substituted 1,2,4-oxadiazole (2025-01-07),

9. 12064418 - Conjoint therapies for immunomodulation (2024-08-20),

10. 12037321 - 1,2,4-oxadiazole derivatives as immunomodulators (2024-07-16),

11. 12005045 - Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds (2024-06-11),

12. 11981685 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2024-05-14),

13. 11866420 - Hydrochloride salt forms of a sulfonamide structured kinase inhibitor (2024-01-09),

14. 11865114 - Method for treating diseases using SMARCA2/4 degraders (2024-01-09),

15. 11633394 - Substituted alkynylene compounds as anticancer agents (2023-04-25),

Aurigene Oncology Limited is a clinical-stage oncology company focused on developing novel therapies for cancer. With a strong pipeline of innovative drug candidates, we are dedicated to improving outcomes for patients with various types of cancer. Our team of experienced researchers and clinicians work tirelessly to advance cutting-edge treatments that have the potential to transform the way cancer is treated. Visit our website to learn more about our approach to oncology research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

16 Patents

#18 in Bengaluru

#113 in India

#36,651 in the World

Bengaluru, India

Aurigene Oncology Limited

Forward Citations = 6

35 inventors:

Muralidhara Ramachandra (8 out of 29 patents)

Pottayil Govindan Nair Sasikumar (5 out of 21 patents)

Susanta Samajdar (5 out of 26 patents)

4. Seetharamaiah Setty Sudarshan Naremaddepalli (4 out of 17 patents)

5. Chennakrishnareddy Gundala (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…